AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI), including those caused by Gram-negative bacteria that represent a ...

AbbVie announced that the US FDA has approved aztreonam and avibactam (Emblaveo), in combination with metronidazole, for adults with complicated intra-abdominal infections who have limited or no ...

AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...

AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in ...

Perhaps shortly after this came the sales forecasts, which at the time were in the region of $5 billion per year at peak. It wasn’t a Humira, but AbbVie was realistic enough to accept that it ...

Three bovine veterinary practitioners had evidence prior infection with highly pathogenic H5N1 avian influenza despite having no apparent contact with infected cows, according to a study published ...

Led by Bosch Ventures, Applyo Jena’s Series A funding seeks to accelerate the development and commercialization of its advanced pharmaceutical technologies.